文献速递心力衰竭与心肌病

多基因风险评分可预测不同心血管风险人群的心力衰竭发生

A Polygenic Risk Score to Predict Incident Heart Failure Across the Spectrum of Cardiovascular Risk.
PubMed 文献 · J Am Coll Cardiol · 2025-08-27

结果显示,中、高遗传风险者新发心衰风险分别增加2倍和5倍,且PRS加入临床模型可改善AUC。结论认为HF PRS是跨心血管风险谱的强独立预测因子。

要点

  • HF PRS高遗传风险者新发心衰风险增加5倍,中风险者增加2倍。
  • 将HF PRS加入临床模型可提高预测心衰的AUC。
  • 在低心血管风险人群中亦观察到一致的预测价值。

核心结论

  • HF PRS是新发心衰的强独立预测因子,适用于不同心血管风险人群。
  • 多基因贡献与现有临床风险评估互补。

研究设计与样本

  • 在6项心血管风险升高患者的试验中,使用Cox-PH模型计算校正临床因素后的心衰住院风险比,并评估区分度和校准度。
  • 在低心血管风险人群中另进行独立数据集分析。
  • 共纳入74,897例无心衰患者,其中51,627例心血管风险升高(中位年龄65岁;男性71%;中位随访2.5年)。

主要发现

  • 校正临床因素后,中遗传风险者新发心衰风险比为2.01(95% CI: 1.62-2.49;P < 0.001)。
  • 高遗传风险者新发心衰风险比为5.00(95% CI: 3.99-6.27;P < 0.001)。
  • 将HF PRS加入临床模型后,AUC从0.787(95% CI: 0.775-0.798)提高至0.822(95% CI: 0.811-0.832)。
  • 在23,270例低心血管风险个体中,经过20年随访,结果一致。

临床怎么用

  • HF PRS可作为临床风险评估的补充工具,用于识别心衰高风险个体。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The clinical utility of a heart failure (HF) polygenic risk score (PRS) is uncertain. OBJECTIVES: The purpose of this study was to investigate the ability of an HF PRS to predict new-onset HF in individuals across the spectrum of cardiovascular risk. METHODS: An HF PRS (>1 million single nucleotide variations) was used to stratify individuals from 7 clinical studies to low (quintile [Q] 1), intermediate (Q2-Q4), or high (Q5) genetic risk. In 6 trials of patients at elevated cardiovascular risk, HRs adjusted for clinical factors were derived for the risk of hospitalization for HF using Cox-PH models, and discrimination and calibration was explored. Analyses were conducted in a separate data set of individuals at low cardiovascular risk. RESULTS: We studied 74,897 patients without HF, of which 51,627 were at elevated cardiovascular risk (median age 65 years; 71% men; median follow-up 2.5 years). After adjusting for clinical factors, individuals with intermediate and high HF PRS carried a 2- and 5-fold increased rate of new-onset HF, respectively (intermediate risk: HRadj: 2.01 [95% CI: 1.62-2.49]; P < 0.001; high-risk: HRadj: 5.00 [95% CI: 3.99-6.27]; P < 0.001). Addition of the HF PRS to a clinical model improved the AUC (0.787 [95% CI: 0.775-0.798] to 0.822 [95% CI: 0.811-0.832]). Results were consistent in 23,270 individuals at low cardiovascular risk over 20-year follow-up. CONCLUSIONS: An HF PRS is a strong and independent predictor for new-onset HF in individuals across the spectrum of cardiovascular risk. The polygenic contribution to HF is complementary to established clinical risk assessment.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Haller, Melloni, Berg, et al. A Polygenic Risk Score to Predict Incident Heart Failure Across the Spectrum of Cardiovascular Risk. J Am Coll Cardiol. 2025. PMID: 40864011. doi:10.1016/j.jacc.2025.06.050

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。